MX2019010725A - Metodos y composiciones para tratar canceres usando antisentido. - Google Patents

Metodos y composiciones para tratar canceres usando antisentido.

Info

Publication number
MX2019010725A
MX2019010725A MX2019010725A MX2019010725A MX2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A
Authority
MX
Mexico
Prior art keywords
compositions
methods
antisense
treating cancers
irradiated
Prior art date
Application number
MX2019010725A
Other languages
English (en)
Inventor
w andrews David
c hooper Douglas
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2019010725A publication Critical patent/MX2019010725A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

La presente invención se refiere a composiciones y métodos para tratar cánceres usando ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina (IGF-1R). El AS puede administrarse a los pacientes por vía sistémica, o puede usarse para producir una vacuna autóloga de células cancerosas. En modalidades, los AS se proporcionan en una cámara de biodifusión irradiada implantable que comprende células tumorales y una cantidad eficaz de AS. Las cámaras se irradian e implantan en el abdomen de los sujetos y estimulan una respuesta inmune que ataca los tumores de manera distal. Las composiciones y métodos descritos en este documento pueden usarse para tratar muchos tipos diferentes de cáncer, por ejemplo, glioblastoma.
MX2019010725A 2017-03-09 2018-03-09 Metodos y composiciones para tratar canceres usando antisentido. MX2019010725A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469003P 2017-03-09 2017-03-09
US201862629972P 2018-02-13 2018-02-13
PCT/US2018/021706 WO2018165528A1 (en) 2017-03-09 2018-03-09 Methods and compositions for treating cancers using antisense

Publications (1)

Publication Number Publication Date
MX2019010725A true MX2019010725A (es) 2020-02-10

Family

ID=62838976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010725A MX2019010725A (es) 2017-03-09 2018-03-09 Metodos y composiciones para tratar canceres usando antisentido.

Country Status (13)

Country Link
US (5) US10357509B2 (es)
EP (1) EP3592841B1 (es)
JP (2) JP2020510021A (es)
KR (1) KR20190140440A (es)
CN (1) CN110832068A (es)
AU (1) AU2018230458A1 (es)
BR (1) BR112019018555A2 (es)
CA (1) CA3054662A1 (es)
MX (1) MX2019010725A (es)
NZ (1) NZ756820A (es)
RU (1) RU2766457C2 (es)
SG (2) SG11201908054XA (es)
WO (1) WO2018165528A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
RU2766457C2 (ru) 2017-03-09 2022-03-15 Томас Джефферсон Юнивёрсити Способы и композиции для лечения рака с помощью антисмысла
JP7406213B2 (ja) * 2018-01-24 2023-12-27 トーマス・ジェファーソン・ユニバーシティ バイオ拡散チャンバおよびその製造方法
WO2020069087A1 (en) * 2018-09-26 2020-04-02 Thomas Jefferson University Neoantigen compositions; and methods of preparation and use thereof
US20220000916A1 (en) * 2018-11-02 2022-01-06 Thomas Jefferson University Methods and compositions for treating breast cancer using antisense
MX2021005169A (es) * 2018-11-02 2021-08-05 Univ Jefferson Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
JP2022527473A (ja) * 2019-03-28 2022-06-02 トーマス・ジェファーソン・ユニバーシティ アンチセンスを用いてがんを治療するための方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
EP0750516A4 (en) 1993-03-26 1998-07-01 Univ Jefferson METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
US6541036B1 (en) * 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
EP1105150A1 (en) * 1998-08-13 2001-06-13 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
NZ541637A (en) 2003-02-11 2008-07-31 Antisense Therapeutics Pty Ltd Modulation of insulin like growth factor I receptor
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
JP6073795B2 (ja) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
US10231817B2 (en) 2013-09-24 2019-03-19 Giner Life Sciences, Inc. System for gas treatment of a cell implant
US9872674B2 (en) * 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
CN108260357A (zh) * 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
EP3285664B1 (en) * 2015-04-23 2021-08-04 Applied Medical Resources Corporation Systems for tissue removal
WO2017066643A1 (en) 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
RU2766457C2 (ru) 2017-03-09 2022-03-15 Томас Джефферсон Юнивёрсити Способы и композиции для лечения рака с помощью антисмысла
JP7406213B2 (ja) 2018-01-24 2023-12-27 トーマス・ジェファーソン・ユニバーシティ バイオ拡散チャンバおよびその製造方法

Also Published As

Publication number Publication date
US20180256625A1 (en) 2018-09-13
JP2020510021A (ja) 2020-04-02
US10357509B2 (en) 2019-07-23
SG11201908054XA (en) 2019-09-27
WO2018165528A1 (en) 2018-09-13
BR112019018555A2 (pt) 2020-04-14
AU2018230458A1 (en) 2019-09-05
RU2019130010A3 (es) 2021-07-05
CA3054662A1 (en) 2018-09-13
EP3592841A4 (en) 2021-01-06
US20240100078A1 (en) 2024-03-28
EP3592841B1 (en) 2024-02-14
EP3592841A1 (en) 2020-01-15
KR20190140440A (ko) 2019-12-19
US11801259B2 (en) 2023-10-31
RU2766457C2 (ru) 2022-03-15
US20190365794A1 (en) 2019-12-05
CN110832068A (zh) 2020-02-21
US20210060055A1 (en) 2021-03-04
US20180201939A1 (en) 2018-07-19
US10772904B2 (en) 2020-09-15
JP2023081916A (ja) 2023-06-13
NZ756820A (en) 2022-08-26
RU2019130010A (ru) 2021-04-10
SG10202109912XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2019010725A (es) Metodos y composiciones para tratar canceres usando antisentido.
JP2019534308A5 (es)
Ngamcherdtrakul et al. In situ tumor vaccination with nanoparticle co‐delivering CpG and STAT3 siRNA to effectively induce whole‐body antitumor immune response
EP4324460A3 (en) Sodium bicarbonate for use in the treatment of gout and related disorders
JP2019504105A5 (es)
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2021003552A (es) Dispositivos implantables para terapia celular y metodos relacionados.
KR20210087949A (ko) 종양내 알파-방출체 방사선 및 세포내 병원체에 대한 세포질 센서의 활성화
MX2021012272A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
WO2021092464A3 (en) Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
EP1723963A3 (en) Hapten-conjugated tumour cells
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
PH12020500666A1 (en) Pladienolide compounds and their use
MX2021005168A (es) Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
Tong et al. Inhibiting human breast cancer cells (mcf-7) with alternating micro-current at intermediate frequency (acif) in vitro and in vivo
WO2022174064A3 (en) Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
JP2022025073A (ja) Ｄｎａ損傷を修復するｒｎａ分子